VCM
RARE icon

Versant Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Versant Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.5K Buy
1,152
+1,001
+663% +$24.9K ﹤0.01% 1542
2026
Q1 		$3.16K Sell
151
-523
-78% -$11.8K ﹤0.01% 2482
2025
Q4 		$15.5K Buy
674
+243
+56% +$7.99K ﹤0.01% 1791
2025
Q3 		$13K Buy
431
+127
+42% +$3.81K ﹤0.01% 1820
2025
Q2 		$11.1K Buy
304
+130
+75% +$4.69K ﹤0.01% 1849
2025
Q1 		$6.3K Buy
174
+15
+9% +$624 ﹤0.01% 1937
2024
Q4 		$6.69K Buy
159
+81
+104% +$4.02K ﹤0.01% 1611
2024
Q3 		$4.33K Hold
78
– – ﹤0.01% 1341
2024
Q2 		$3.21K Buy
+78
New +$3.33K ﹤0.01% 1363
2023
Q3 		– Sell
-12
Closed -$554 – 2034
2023
Q2 		$554 Buy
+12
New +$557 ﹤0.01% 1810

Other funds holding RARE

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return

Versant Capital Management's RARE Position: Q2 2026 in Review

Versant Capital Management increased its Ultragenyx Pharmaceutical (RARE) stake by 663% in Q2 2026, buying an estimated $24.9K and bringing the position to 1,152 shares worth $38.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1542.

Versant Capital Management first reported a position in RARE in Q2 2023 and has held it in 10 quarters since. 24 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Versant Capital Management held 1,152 shares of Ultragenyx Pharmaceutical worth $38.5K as of Q2 2026.
  • Versant Capital Management bought 1,001 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $24.9K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1542 holding.
  • Versant Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and has held it in 10 quarters since.
  • 24 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.